Tg Therapeutics (TGTX)

$30.60 -0.20 (-0.65%)
Market Cap 4.87B
Revenue (ttm) 329.00M
Net Income (ttm) 23.38M
EPS (ttm) N/A
PE Ratio 11.22
Forward PE 17.28
Profit Margin 7.11%
Debt to Equity Ratio 0.40
Volume 513,793
Avg Vol 1,937,528
Day's Range N/A - N/A
Shares Out 158.76M
Stochastic %K 49%
Beta 1.86
Analysts Strong Sell
Price Target $44.86

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's de...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 554 4484
Fax: 212 554 4531
Address:
3020 Carrington Mill Blvd., Suite 475, Morrisville, United States
SCCT2FL
SCCT2FL Jan. 28 at 5:38 PM
$TGTX seems like you can sell at $32 and buy back a few days later at $30 just over and over again. It's stuck for now, may as well milk the trend
1 · Reply
WolfOfBaySt2025
WolfOfBaySt2025 Jan. 28 at 4:50 PM
$TGTX We’re cooked . He won’t sell for 65 , he is still milking this for shares every year , and what is the investor getting ? The opportunity cost here are adding up .
0 · Reply
Quad_
Quad_ Jan. 28 at 4:35 PM
$TGTX Sell it, Mike.
0 · Reply
stocky1234
stocky1234 Jan. 28 at 4:17 PM
$TGTX
0 · Reply
Sciguy67
Sciguy67 Jan. 28 at 4:14 PM
$TGTX my feeling is MW is realizing he needs to sell while he still can. This one trick pony is running out of tricks. BO $65 is my estimate
1 · Reply
StockDreamin
StockDreamin Jan. 28 at 3:25 PM
$TGTX cmon cmon
0 · Reply
greko50
greko50 Jan. 28 at 2:40 PM
$TGTX During next months 4Q ER I bet MW announces an increase to the share buyback program, going to at least $200 mil from $100 mil. Maybe that will kickstart things, as we have hit a major lull.......
2 · Reply
TheGunnerAB
TheGunnerAB Jan. 28 at 1:29 PM
$TGTX so IBRX short Interest goes to all time high of 127M shares on 1/15. The stock goes from $2 to over $8.X in one week, raping all shorts without condom, forcing them to go to the ER. Short interest means nothing, so many companies with a very large short interest were acquired at very high SI causing huge lines at different ERs around the country.
4 · Reply
calbucs
calbucs Jan. 28 at 1:26 PM
$TGTX Here is the reason why we are stuck in the low $30’s , a huge uptake on Short interest of almost 2 mill , crazy !!! 27.2 Mil , 4 consecutive updates where they have upped the Short interest . This started back in October / November of LY . Mike needs to bring the hammer on next Quarterly results !!
0 · Reply
Luckybreak
Luckybreak Jan. 28 at 1:15 PM
$TGTX What has love got to do with it What has short interest got to do with it Immuno medic was acquired by Gilead for 21 billion with a large short interest . Do your home work,know what you own/exactly what has love got to do with it
2 · Reply
Latest News on TGTX
These under-the-radar stocks combine fast growth with big upside potential

Jan 15, 2026, 10:31 AM EST - 13 days ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

TG Therapeutics: The "Exit Velocity" You Can't Ignore (Rating Upgrade)

Jan 15, 2026, 10:24 AM EST - 13 days ago

TG Therapeutics: The "Exit Velocity" You Can't Ignore (Rating Upgrade)

TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 6:46 PM EST - 14 days ago

TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

TG Therapeutics Stock Climbs After The Bell: Here's Why

Jan 13, 2026, 5:05 PM EST - 14 days ago

TG Therapeutics Stock Climbs After The Bell: Here's Why

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 21 days ago

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

TG Therapeutics: What Wall Street Isn't Telling You

Dec 30, 2025, 11:00 AM EST - 4 weeks ago

TG Therapeutics: What Wall Street Isn't Telling You

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 28, 2025, 7:30 AM EST - 2 months ago

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

TG Therapeutics: Concerns About Slowing Growth And New Competition

Nov 18, 2025, 5:23 PM EST - 2 months ago

TG Therapeutics: Concerns About Slowing Growth And New Competition

TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing

Nov 17, 2025, 5:49 PM EST - 2 months ago

TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing

TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows

Nov 3, 2025, 3:48 PM EST - 3 months ago

TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows

TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 11:56 AM EST - 3 months ago

TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

Oct 31, 2025, 7:30 AM EDT - 3 months ago

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

Oct 28, 2025, 7:30 AM EDT - 3 months ago

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Sep 24, 2025, 9:10 AM EDT - 4 months ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Sep 10, 2025, 7:30 AM EDT - 5 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Sep 8, 2025, 7:30 AM EDT - 5 months ago

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

TG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 7:57 AM EDT - 5 months ago

TG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 Transcript

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 5 months ago

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Sep 3, 2025, 7:30 AM EDT - 5 months ago

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 28, 2025, 8:00 AM EDT - 5 months ago

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 10:19 AM EDT - 6 months ago

TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Aug 4, 2025, 7:00 AM EDT - 6 months ago

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

Jul 30, 2025, 7:30 AM EDT - 6 months ago

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel

Jun 25, 2025, 4:05 PM EDT - 7 months ago

TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

Jun 9, 2025, 4:51 PM EDT - 8 months ago

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

CNS LEU RMBS SFM

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 7:30 AM EDT - 8 months ago

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

TG Therapeutics: Estimates Could Soon Be Raised Again

May 28, 2025, 6:00 AM EDT - 8 months ago

TG Therapeutics: Estimates Could Soon Be Raised Again

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 27, 2025, 7:30 AM EDT - 8 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

May 5, 2025, 4:37 PM EDT - 9 months ago

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges

May 5, 2025, 1:30 PM EDT - 9 months ago

TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges

TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:55 AM EDT - 9 months ago

TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

May 5, 2025, 7:00 AM EDT - 9 months ago

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

Apr 30, 2025, 7:30 AM EDT - 9 months ago

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Apr 10, 2025, 7:30 AM EDT - 10 months ago

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Apr 7, 2025, 7:30 AM EDT - 10 months ago

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher

Mar 21, 2025, 11:50 AM EDT - 11 months ago

Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher

Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel

Mar 15, 2025, 8:42 AM EDT - 11 months ago

Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel

TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials

Mar 14, 2025, 2:04 PM EDT - 11 months ago

TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials

TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter

Mar 12, 2025, 4:11 PM EDT - 11 months ago

TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Mar 7, 2025, 7:30 AM EST - 11 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

Mar 4, 2025, 7:03 AM EST - 11 months ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

CORT GILD PRVA TKO

TG Therapeutics: A Wonderful Hold

Mar 3, 2025, 3:59 PM EST - 11 months ago

TG Therapeutics: A Wonderful Hold

TG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 11:55 AM EST - 11 months ago

TG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 27, 2025, 7:30 AM EST - 11 months ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 26, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

TG Therapeutics: Entering 2025 With Increased Investor Expectations

Jan 23, 2025, 2:48 PM EST - 1 year ago

TG Therapeutics: Entering 2025 With Increased Investor Expectations

TG Therapeutics: 2025 Revenues Will Smash Expectations

Jan 21, 2025, 2:17 AM EST - 1 year ago

TG Therapeutics: 2025 Revenues Will Smash Expectations

TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst

Jan 13, 2025, 11:38 PM EST - 1 year ago

TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SCCT2FL
SCCT2FL Jan. 28 at 5:38 PM
$TGTX seems like you can sell at $32 and buy back a few days later at $30 just over and over again. It's stuck for now, may as well milk the trend
1 · Reply
WolfOfBaySt2025
WolfOfBaySt2025 Jan. 28 at 4:50 PM
$TGTX We’re cooked . He won’t sell for 65 , he is still milking this for shares every year , and what is the investor getting ? The opportunity cost here are adding up .
0 · Reply
Quad_
Quad_ Jan. 28 at 4:35 PM
$TGTX Sell it, Mike.
0 · Reply
stocky1234
stocky1234 Jan. 28 at 4:17 PM
$TGTX
0 · Reply
Sciguy67
Sciguy67 Jan. 28 at 4:14 PM
$TGTX my feeling is MW is realizing he needs to sell while he still can. This one trick pony is running out of tricks. BO $65 is my estimate
1 · Reply
StockDreamin
StockDreamin Jan. 28 at 3:25 PM
$TGTX cmon cmon
0 · Reply
greko50
greko50 Jan. 28 at 2:40 PM
$TGTX During next months 4Q ER I bet MW announces an increase to the share buyback program, going to at least $200 mil from $100 mil. Maybe that will kickstart things, as we have hit a major lull.......
2 · Reply
TheGunnerAB
TheGunnerAB Jan. 28 at 1:29 PM
$TGTX so IBRX short Interest goes to all time high of 127M shares on 1/15. The stock goes from $2 to over $8.X in one week, raping all shorts without condom, forcing them to go to the ER. Short interest means nothing, so many companies with a very large short interest were acquired at very high SI causing huge lines at different ERs around the country.
4 · Reply
calbucs
calbucs Jan. 28 at 1:26 PM
$TGTX Here is the reason why we are stuck in the low $30’s , a huge uptake on Short interest of almost 2 mill , crazy !!! 27.2 Mil , 4 consecutive updates where they have upped the Short interest . This started back in October / November of LY . Mike needs to bring the hammer on next Quarterly results !!
0 · Reply
Luckybreak
Luckybreak Jan. 28 at 1:15 PM
$TGTX What has love got to do with it What has short interest got to do with it Immuno medic was acquired by Gilead for 21 billion with a large short interest . Do your home work,know what you own/exactly what has love got to do with it
2 · Reply
PotionX1900
PotionX1900 Jan. 28 at 1:10 PM
$TGTX I can tell the shorts are desperate because of all this pre market BS. Nobody does that unless they have a purpose. It’s almost every day too.
0 · Reply
Rutgers
Rutgers Jan. 28 at 1:06 PM
$TGTX Seeing high 30’s pre-market….and announced 2/5 conf to share new Briumvi studies, making the rounds. Can we just get the BO news release please…oh, where is the Shartist? Bummed, I’m blocked..
1 · Reply
WolfOfBaySt2025
WolfOfBaySt2025 Jan. 28 at 12:52 PM
$TGTX Shorts almost back to ATH , so cult members , do you believe you're smarter than hedge funds placing these large bets ? The company is not getting sold anytime soon. They’re not scared of Mike . We will be pinned for the year .
0 · Reply
Sciguy67
Sciguy67 Jan. 28 at 1:48 AM
$TGTX overnight trading shows a drop to $29.76
4 · Reply
ern1in
ern1in Jan. 28 at 1:02 AM
$TGTX @TroyTiger 🐅🐅🐅🐅🐅
0 · Reply
Rickerthestockpicker
Rickerthestockpicker Jan. 28 at 12:33 AM
$TGTX I believe much much more news will come out about the Saudi Investment in IBRX along with positive ANKTIVA news soon Long with TGTX and IBRX
0 · Reply
ern1in
ern1in Jan. 28 at 12:25 AM
$TGTX / BRIUMVI / SUB-Q 🏒
0 · Reply
ern1in
ern1in Jan. 28 at 12:21 AM
$TGTX First time ! I just saw our BRIUMVI commercial on MSG > MADISON SQUARE GARDEN CHANNEL ! HELL, YEA !!!!!!! 😝😝😝😝😝😝😝😝😝
0 · Reply
BioHedge
BioHedge Jan. 27 at 10:58 PM
$TGTX We’ve got a lot of Negative Nancys on here.
1 · Reply
Luckybreak
Luckybreak Jan. 27 at 10:25 PM
$TGTX Minimum $80 plus stock any which way you dice it BO or no BO
1 · Reply
WolfOfBaySt2025
WolfOfBaySt2025 Jan. 27 at 9:25 PM
$TGTX The quicker you all come to the realization that the below is NOT happening the faster we can work together to drive change . But this cult talk has to stop . When was Mikes last open market buy !? Hes too busy taking free shares .
0 · Reply
stu
stu Jan. 27 at 9:04 PM
$TGTX SI: notable increase in SI for the period ended 1/15/26 by 6.71%.
1 · Reply